Hostname: page-component-76fb5796d-vfjqv Total loading time: 0 Render date: 2024-04-26T09:55:07.527Z Has data issue: false hasContentIssue false
  • English
  • Français

Modulating the serotonin system in the treatment of major depressive disorder

Published online by Cambridge University Press:  29 December 2014

Debbi Ann Morrissette  and
Stephen M. Stahl
Debbi Ann Morrissette*
Affiliation:
Neuroscience Education Institute, Carlsbad, CA, USA Department of Biology, Palomar College, San Marcos, CA, USA Department of Biology, California State University, San Marcos, CA, USA
Stephen M. Stahl
Affiliation:
Neuroscience Education Institute, Carlsbad, CA, USA Department of Psychiatry, University of California, San Diego, USA Department of Psychiatry, University of Cambridge, UK
*
*Address for correspondence: (Email: dmorrissette@neiglobal.com)
Get access Rights & Permissions [Opens in a new window]

Abstract

Learning Objective: Discuss the theory of modulation of receptor activity or the blockade of the reuptake of multiple neurotransmitter systems for the future treatment of MDD.

Major depressive disorder (MDD) is a serious and often crippling psychiatric illness with a high risk of relapse and treatment resistance. In this article, we discuss the role of the serotonergic system in MDD including our current understanding of how various serotonin (5HT) receptors modulate monoamine neurotransmission and behavior. We also discuss how pharmacologic interventions, including novel and existing antidepressants and atypical antipsychotics, may be utilized to adjust serotonergic neurotransmission and provide more effective treatments for patients with MDD.

Keywords

atypical antipsychoticserotoninSERTvortioxetinevilazodone
Type
CME Review Article
Information
CNS Spectrums , Volume 19 , Issue S1: CME SUPPLEMENT , December 2014 , pp. 54 - 68
Copyright
© Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

This activity is supported by an educational grant from Takeda Pharmaceuticals International, Inc.

References

1.US Burden of Disease Collaborators. The state of US health, 1990–2010: burden of diseases, injuries, and risk factors. JAMA. 2013; 310(6): 591–608.Google Scholar
2.Bulloch, A, Williams, J, Lavorato, D, Patten, S. Recurrence of major depressive episodes is strongly dependent on the number of previous episodes. Depress Anxiety. 2014; 31(1): 72–76.CrossRefGoogle ScholarPubMed
3.Marazziti, D. Depression and serotonin: a never ending story. Curr Drug Targets. 2013; 14(5): 513.Google Scholar
4.Stahl, SM. Stahl's Essential Psychopharmacology. 4th ed.New York: Cambridge University Press; 2013.Google Scholar
5.Mann, JJ. The serotonergic system in mood disorders and suicidal behaviour. Philos Trans R Soc Lond B Biol Sci. 2013; 368(1615): 20120537.CrossRefGoogle ScholarPubMed
6.Shimizu, S, Mizuguchi, Y, Ohno, Y. Improving the treatment of schizophrenia: role of 5-HT receptors in modulating cognitive and extrapyramidal motor functions. CNS Neurol Disord Drug Targets. 2013; 12(6): 861–869.CrossRefGoogle ScholarPubMed
7.Artigas, F. Serotonin receptors involved in antidepressant effects. Pharmacol Ther. 2013; 137(1): 119–131.Google Scholar
8.Carr, GV, Lucki, I. The role of serotonin receptor subtypes in treating depression: a review of animal studies. Psychopharmacology (Berl). 2011; 213(2–3): 265–287.Google Scholar
9.Ohno, Y, Shimizu, S, Tokudome, K. Pathophysiological roles of serotonergic system in regulating extrapyramidal motor functions. Biol Pharm Bull. 2013; 36(9): 1396–1400.CrossRefGoogle ScholarPubMed
10.Ramirez, MJ, Lai, MK, Tordera, RM, Francis, PT. Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status. Drugs. 2014; 74(7): 729–736.Google Scholar
11.Sari, Y. Serotonin1B receptors: from protein to physiological function and behavior. Neurosci Biobehav Rev. 2004; 28(6): 565–582.Google Scholar
12.Bonaventure, P, Kelly, L, Aluisio, L, et al. Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents. J Pharmacol Exp Ther. 2007; 321(2): 690–698.Google Scholar
13.Hopwood, SE, Stamford, JA. Multiple 5-HT(1) autoreceptor subtypes govern serotonin release in dorsal and median raphe nuclei. Neuropharmacology. 2001; 40(4): 508–519.Google Scholar
14.Khundakar, AA, Thomas, AJ. Neuropathology of depression in Alzheimer’s disease: current knowledge and the potential for new treatments. J Alzheimers Dis. Epub ahead of print.Google Scholar
15.Baron, KG, Reid, KJ. Circadian misalignment and health. Int Rev Psychiatry. 2014; 26(2): 139–154.CrossRefGoogle ScholarPubMed
16.Karatsoreos, IN. Links between circadian rhythms and psychiatric disease. Front Behav Neurosci. 2014; 8: 162.Google Scholar
17.Tokarski, K, Kusek, M, Sowa, J, Bobula, B. Possible involvement of 5-HT7 receptor in pathophysiology of affective disorders and action of antidepressant drugs. Postepy Hig Med Dosw (Online). 2014; 68: 1104–1113.Google Scholar
18.Roberts, AJ, Hedlund, PB. The 5-HT(7) receptor in learning and memory. Hippocampus. 2012; 22(4): 762–771.Google Scholar
19.Stahl, SM, Lee-Zimmerman, C, Cartwright, S, Morrissette, DA. Serotonergic drugs for depression and beyond. Curr Drug Targets. 2013; 14(5): 578–585.Google Scholar